Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
| Autor: | Malgorzata W. Kimsa, Maria Formińska-Kapuścik, Katarzyna Michalska-Małecka, Adam Kabiesz, Urszula Mazurek, Barbara Strzalka-Mrozik, Małgorzata Nita |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
Visual acuity genetic structures Visual Acuity Angiogenesis Inhibitors chemistry.chemical_compound 0302 clinical medicine Gene expression 030212 general & internal medicine Original Research Aged 80 and over General Medicine Middle Aged Bevacizumab medicine.anatomical_structure Intravitreal Injections Female medicine.symptom Corrigendum Tomography Optical Coherence medicine.drug medicine.medical_specialty Peripheral blood mononuclear cell Retina 03 medical and health sciences Ophthalmology Ranibizumab medicine Humans contralateral eye Aged business.industry oligonucleotide microarray Retinal Macular degeneration medicine.disease eye diseases chemistry Clinical Interventions in Aging 030221 ophthalmology & optometry Leukocytes Mononuclear Wet Macular Degeneration sense organs Poland Geriatrics and Gerontology business Transcriptome central retinal thickness |
| Zdroj: | Clinical Interventions in Aging |
| ISSN: | 1178-1998 |
| Popis: | Katarzyna Michalska-MaÅecka,1,2 Adam Kabiesz,2 Malgorzata W Kimsa,3 Barbara StrzaÅka-Mrozik,3 Maria FormiÅska-KapuÅcik,2,4 Malgorzata Nita,5 Urszula Mazurek31Clinical Department of Ophthalmology, Medical University of Silesia, Katowice, Poland; 2University Center for Ophthalmology and Oncology, Independent Public Clinical Hospital, Medical University of Silesia, Katowice, Poland; 3Department of Molecular Biology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia, Katowice, Poland; 4Clinical Department of Children Ophthalmology, Medical University of Silesia, Katowice, Poland; 5Domestic and Specialized Medicine Centre “Dilmed”, Katowice, PolandAbstract: The purpose of this study was to evaluate the systemic effects of intravitreal ranibizumab (Lucentis) treatment in patients with neovascular age-related macular degeneration (AMD). The impact of intravitreal ranibizumab injections on central retinal thickness (CRT) of treated and contralateral untreated eyes, and differences in gene expression patterns in the peripheral blood mononuclear cells were analyzed. The study included 29 patients aged 50years old and over with diagnosed neovascular AMD. The treatment was defined as 0.5 mg of ranibizumab injected intravitreally in the form of one injection every month during the period of 3 months. CRT was measured by optical coherence tomography. The gene expression profile was assigned using oligonucleotide microarrays of Affymetrix HG-U133A. Studies have shown that there was a change of CRT between treated and untreated eyes, and there were differences in CRT at baseline and after 1, 2, and 3 months of ranibizumab treatment. Three months after intravitreal injection, mean CRT was reduced in the treated eyes from 331.97±123.62 to 254.31±58.75 µm, while mean CRT in the untreated fellow eyes reduced from 251.07±40.29 to 235.45±36.21 µm at the same time. Furthermore, the research has shown that among all transcripts, 3,097 expresses change after the ranibizumab treatment in relation to controls. Among these transcripts, 1,339 were up-regulated, whereas 1,758 were down-regulated. Our results show the potential systemic effects of anti-VEGF therapy for AMD. Moreover, our study indicated different gene expression in peripheral blood mononuclear cells before and after intravitreal ranibizumab treatment. Keywords: ranibizumab, contralateral eye, central retinal thickness, oligonucleotide microarrayCorrigendum for this paper has been published. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|